Outlook Therapeutics (OTLK) Price & Analysis

Compare

1,484 Followers

OTLK Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.79 - $6.98

Previous CloseN/A

Volume358.39K

Average Volume (3M)6.02M

Market Cap

$46.64M

Enterprise Value$84.93M

Total Cash (Recent Filing)$8.90M

Total Debt (Recent Filing)$34.70M

Price to Earnings (P/E)―

Beta0.40

Next Earnings

Dec 18, 2025

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.44

Shares Outstanding44,419,530

10 Day Avg. Volume3,550,435

30 Day Avg. Volume6,021,546

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)-1.36

Price to Sales (P/S)0.00

P/FCF Ratio-1.44

Enterprise Value/Market Cap1.82

Enterprise Value/Revenue50.69

Enterprise Value/Gross Profit77.72

Enterprise Value/Ebitda-1.76

Forecast

1Y Price Target

$2.00

Price Target Upside85.19% Upside

Rating ConsensusHold

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Competitive AdvantageManagement is confident in Lytenava's ability to compete effectively in both countries given its regulatory approval and price advantage.

European Market ExpansionExpansion into other European countries, starting in Austria and the Netherlands, could drive further growth.

Bears Say

FDA Approval ChallengesConcerns remain about whether the BLA resubmission of ONS-5010 is sufficient to secure an FDA approval.

Financial StabilityFinancing continues to be a major overhang on the name; with cash guidance only for the next 3 months, there are serious doubts on the company's ability to get ONS-5010 approved in the U.S.

Outlook Therapeutics News

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Outlook Therapeutics Inc (OTLK)...

2d ago

RDW

KYIV

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Outlook Therapeutics Inc (OTLK)...

8d ago

RDW

BULL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Outlook Therapeutics Inc (OTLK)...

15d ago

LIT

Outlook Therapeutics submits Type A meeting request to FDA

Outlook Therapeutics (OTLK) announced that a Type A Meeting request has been submitted to the U.S. Food and...

17d ago

OTLK

Marvell downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

21d ago

AHL

SWX

Outlook Therapeutics downgraded to Neutral yesterday at Guggenheim after CRL

As previously reported yesterday, Guggenheim downgraded Outlook Therapeutics (OTLK) to Neutral from Buy and removed the firm’s price...

21d ago

OTLK

Outlook Therapeutics downgraded at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao downgraded Outlook Therapeutics (OTLK) with a price target of $1, down from $3....

21d ago

OTLK

Outlook CRL ‘a significant setback,’ doesn’t mean end for Lytenava, says Chardan

After Outlook Therapeutics (OTLK) announced that it received a complete response letter from the FDA for Lytenava in...

22d ago

OTLK

Outlook Therapeutics downgraded to Neutral from Buy at Guggenheim

Guggenheim downgraded Outlook Therapeutics (OTLK) to Neutral from Buy. Published first on TheFly – the ultimate source for...

22d ago

OTLK

Outlook Therapeutics’ resubmission for wet AMD candidate rejected by FDA

Outlook Therapeutics (OTLK) announced that the FDA has issued a complete response letter, or CRL, to its biologics...

22d ago

OTLK

Outlook Therapeutics CCO Jeff Evanson Steps Down

Outlook Therapeutics ( ($OTLK) ) has provided an announcement. On September 5, 2025, Jeff Evanson stepped down as...

13d ago

OTLK

FDA Issues Complete Response Letter to Outlook Therapeutics

Outlook Therapeutics ( ($OTLK) ) has issued an update. On August 28, 2025, Outlook Therapeutics announced that the...

16d ago

OTLK

Hold Rating for Outlook Therapeutics Amid FDA Setbacks and Financial Challenges

H.C. Wainwright analyst Douglas Tsao downgraded the rating on Outlook Therapeutics to a Hold today, setting a price...

21d ago

OTLK

Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies

Outlook Therapeutics (OTLK) has disclosed a new risk, in the Capital Markets category. Outlook Therapeutics faces significant risks...

1M ago

OTLK

OTLK FAQ

What was Outlook Therapeutics’s price range in the past 12 months?

Outlook Therapeutics lowest stock price was $0.79 and its highest was $6.98 in the past 12 months.

What is Outlook Therapeutics’s market cap?

Outlook Therapeutics’s market cap is $46.64M.

When is Outlook Therapeutics’s upcoming earnings report date?

Outlook Therapeutics’s upcoming earnings report date is Dec 18, 2025 which is in 90 days.

How were Outlook Therapeutics’s earnings last quarter?

Outlook Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.088.

Is Outlook Therapeutics overvalued?

According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Outlook Therapeutics pay dividends?

Outlook Therapeutics does not currently pay dividends.

What is Outlook Therapeutics’s EPS estimate?

Outlook Therapeutics’s EPS estimate is -0.24.

How many shares outstanding does Outlook Therapeutics have?

Outlook Therapeutics has 44,419,530 shares outstanding.

What happened to Outlook Therapeutics’s price movement after its last earnings report?

Outlook Therapeutics reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went up 14.085%.

Which hedge fund is a major shareholder of Outlook Therapeutics?

Currently, no hedge funds are holding shares in OTLK

Outlook Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

<0.01%

Trailing 12-Months

Asset Growth

-52.45%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Outlook Therapeutics

Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody therapies. The company is primarily engaged in the research and development of therapeutics in the field of ophthalmology. Its leading product candidate is ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation designed for use in treating wet age-related macular degeneration (AMD) and other retinal diseases.

Outlook Therapeutics (OTLK) Earnings & Revenues

Historic Earnings Reports

OTLK Stock 12 Month Forecast

Average Price Target

$2.00

▲(85.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.93,2.0123076923076924,2.0946153846153845,2.1769230769230767,2.2592307692307694,2.3415384615384616,2.4238461538461538,2.506153846153846,2.5884615384615386,2.670769230769231,2.753076923076923,2.8353846153846156,2.917692307692308,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.93,1.9353846153846153,1.9407692307692308,1.9461538461538461,1.9515384615384614,1.956923076923077,1.9623076923076923,1.9676923076923076,1.973076923076923,1.9784615384615385,1.9838461538461538,1.9892307692307691,1.9946153846153847,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.93,1.8584615384615384,1.7869230769230768,1.7153846153846153,1.6438461538461537,1.5723076923076922,1.5007692307692309,1.4292307692307693,1.3576923076923078,1.2861538461538462,1.2146153846153847,1.143076923076923,1.0715384615384616,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.13,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.5,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >